Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single center, open-label, dose-escalating, Phase I study to evaluate the safety of GX-188E administered by electroporation (EP) in DNA-based therapeutic vaccine for patients with Cervical Intraepithelial Neoplasia grade 3 (CIN 3)

Next Previous
X
Search
Trial Profile

A single center, open-label, dose-escalating, Phase I study to evaluate the safety of GX-188E administered by electroporation (EP) in DNA-based therapeutic vaccine for patients with Cervical Intraepithelial Neoplasia grade 3 (CIN 3)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GX 188E (Primary)
  • Indications Cervical intraepithelial neoplasia
  • Focus Adverse reactions
  • Sponsors Genexine

    • Most Recent Events

    • 10 Mar 2014 Status changed from recruiting to completed, as per Korean Clinical Trials Register record.
    • 13 Feb 2013 New source identified and integrated (KCT0000586: Clinical Research Information Service (CriS) - Republic of Korea).
    • 12 Nov 2012 Status changed from not yet recruiting to recruiting as reported by Korean Clinical Trials Register.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top